The University of Chicago Header Logo

Connection

Ted Skolarus to Male

Back to Details
This is a "connection" page, showing publications Ted Skolarus has written about Male.
Ted Skolarus
Connection Strength
2.382
Male
  1. Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer. Cancer Med. 2024 Jun; 13(12):e7334.
    View in: PubMed
    Score: 0.048
  2. Primary Care Physician and Urologist Perspectives on Optimizing Active Surveillance for Low-Risk Prostate Cancer. Ann Fam Med. 2024 Jan-Feb; 22(1):5-11.
    View in: PubMed
    Score: 0.047
  3. National Long-term Survival Estimates After Radical Prostatectomy for Prostate Cancer. Urology. 2024 02; 184:135-141.
    View in: PubMed
    Score: 0.046
  4. Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system. Cancer. 2023 10 15; 129(20):3326-3333.
    View in: PubMed
    Score: 0.045
  5. Differential adoption of castration-resistant prostate cancer treatment across facilities in a national healthcare system. Cancer Med. 2023 03; 12(6):6945-6955.
    View in: PubMed
    Score: 0.044
  6. Understanding the Role of Urology Practice Organization and Racial Composition in Prostate Cancer Treatment Disparities. JCO Oncol Pract. 2023 05; 19(5):e763-e772.
    View in: PubMed
    Score: 0.044
  7. Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy. JNCI Cancer Spectr. 2022 05 02; 6(3).
    View in: PubMed
    Score: 0.042
  8. Prostate cancer clinical trial completion: The role of geography. Contemp Clin Trials. 2021 12; 111:106600.
    View in: PubMed
    Score: 0.040
  9. Factors influencing treatment of veterans with advanced prostate cancer. Cancer. 2021 07 01; 127(13):2311-2318.
    View in: PubMed
    Score: 0.039
  10. Reframing Financial Incentives Around Reducing Readmission After Radical Cystectomy. Urology. 2020 08; 142:99-105.
    View in: PubMed
    Score: 0.036
  11. Dynamic readmission prediction using routine postoperative laboratory results after radical cystectomy. Urol Oncol. 2020 04; 38(4):255-261.
    View in: PubMed
    Score: 0.036
  12. Characterizing the Benign Prostatic Hyperplasia Literature: A Bibliometric Analysis. Urology. 2020 Feb; 136:202-211.
    View in: PubMed
    Score: 0.035
  13. Catheter management after benign transurethral prostate surgery: RAND/UCLA Appropriateness Criteria. Am J Manag Care. 2019 12 01; 25(12):e366-e372.
    View in: PubMed
    Score: 0.035
  14. Association between PSA values and surveillance quality after prostate cancer surgery. Cancer Med. 2019 12; 8(18):7903-7912.
    View in: PubMed
    Score: 0.035
  15. Inaugural Readmission Penalties for Total Hip and Total Knee Arthroplasty Procedures Under the Hospital Readmissions Reduction Program. JAMA Netw Open. 2019 11 01; 2(11):e1916008.
    View in: PubMed
    Score: 0.035
  16. Determinants of quality prostate cancer survivorship care across the primary and specialty care interface: Lessons from the Veterans Health Administration. Cancer Med. 2019 05; 8(5):2686-2702.
    View in: PubMed
    Score: 0.034
  17. Self-Management in Long-Term Prostate Cancer Survivors: A Randomized, Controlled Trial. J Clin Oncol. 2019 05 20; 37(15):1326-1335.
    View in: PubMed
    Score: 0.034
  18. De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT). Implement Sci. 2018 11 29; 13(1):144.
    View in: PubMed
    Score: 0.033
  19. Characterising potential bone scan overuse amongst men treated with radical prostatectomy. BJU Int. 2019 07; 124(1):55-61.
    View in: PubMed
    Score: 0.033
  20. Castration remains despite decreasing definitive treatment of localized prostate cancer in the elderly: A case for de-implementation. Cancer. 2018 10 15; 124(20):3971-3974.
    View in: PubMed
    Score: 0.032
  21. Dissecting Surgeon Behavior: Leveraging the Theoretical Domains Framework to Facilitate Evidence-based Surgical Practice. Ann Surg. 2018 03; 267(3):432-434.
    View in: PubMed
    Score: 0.031
  22. The implications of baseline bone-health assessment at initiation of androgen-deprivation therapy for prostate cancer. BJU Int. 2018 04; 121(4):558-564.
    View in: PubMed
    Score: 0.031
  23. Multilingual Self-Management Resources for Prostate Cancer Survivors and Their Partners: Results of a Long-Term Academic-State Health Department Partnership to Promote Survivorship Care. Urology. 2017 Dec; 110:92-97.
    View in: PubMed
    Score: 0.030
  24. Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D. J Oncol Pract. 2017 08; 13(8):e694-e702.
    View in: PubMed
    Score: 0.030
  25. Enhancing prostate cancer survivorship care through self-management. Urol Oncol. 2017 09; 35(9):564-568.
    View in: PubMed
    Score: 0.030
  26. Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial. Trials. 2017 04 18; 18(1):181.
    View in: PubMed
    Score: 0.029
  27. No Differences in Population-based Readmissions After Open and Robotic-assisted Radical Cystectomy: Implications for Post-discharge Care. Urology. 2017 06; 104:77-83.
    View in: PubMed
    Score: 0.029
  28. Variation in readmission expenditures after high-risk surgery. J Surg Res. 2017 06 01; 213:60-68.
    View in: PubMed
    Score: 0.029
  29. Implications of Prostate Cancer Treatment in Men With Inflammatory Bowel Disease. Urology. 2017 06; 104:131-136.
    View in: PubMed
    Score: 0.029
  30. Providing prostate cancer survivorship care in Japan: Implications from the USA care model. Int J Urol. 2016 11; 23(11):906-915.
    View in: PubMed
    Score: 0.028
  31. Treatment of ureteral anastomotic strictures with reimplantation and survival after cystectomy and urinary diversion. Urol Oncol. 2017 01; 35(1):33.e1-33.e9.
    View in: PubMed
    Score: 0.028
  32. The Fate of Radical Cystectomy Patients after Hospital Discharge: Understanding the Black Box of the Pre-readmission Interval. Eur Urol Focus. 2018 09; 4(5):711-717.
    View in: PubMed
    Score: 0.028
  33. Re: Neil E. Martin, Laura Massey, Caleb Stowell, et al. Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. Eur Urol 2015;67:460-7. Eur Urol. 2016 06; 69(6):e125-6.
    View in: PubMed
    Score: 0.027
  34. Symptom burden and information needs in prostate cancer survivors: a case for tailored long-term survivorship care. BJU Int. 2016 09; 118(3):372-8.
    View in: PubMed
    Score: 0.027
  35. Editorial comment. Urology. 2015 Mar; 85(3):627-8.
    View in: PubMed
    Score: 0.025
  36. Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. Urology. 2015 Jan; 85(1):101-5.
    View in: PubMed
    Score: 0.025
  37. Understanding hospital readmission intensity after radical cystectomy. J Urol. 2015 May; 193(5):1500-6.
    View in: PubMed
    Score: 0.025
  38. Androgen-deprivation-associated bone disease. Curr Opin Urol. 2014 Nov; 24(6):601-7.
    View in: PubMed
    Score: 0.025
  39. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin. 2014 Jul-Aug; 64(4):225-49.
    View in: PubMed
    Score: 0.024
  40. Sharpening the focus on causes and timing of readmission after radical cystectomy for bladder cancer. Cancer. 2014 May 01; 120(9):1409-16.
    View in: PubMed
    Score: 0.024
  41. Quality of prostate cancer care among rural men in the Veterans Health Administration. Cancer. 2013 Oct 15; 119(20):3629-35.
    View in: PubMed
    Score: 0.023
  42. Editorial comment. Urology. 2013 Apr; 81(4):751.
    View in: PubMed
    Score: 0.022
  43. Evidence of perineural invasion on prostate biopsy specimen and survival after radical prostatectomy. Urology. 2013 Feb; 81(2):354-7.
    View in: PubMed
    Score: 0.022
  44. Monitoring quality of life among prostate cancer survivors: the feasibility of automated telephone assessment. Urology. 2012 Nov; 80(5):1021-6.
    View in: PubMed
    Score: 0.021
  45. Use of restaging bladder tumor resection for bladder cancer among Medicare beneficiaries. Urology. 2011 Dec; 78(6):1345-9.
    View in: PubMed
    Score: 0.020
  46. Understanding fragmentation of prostate cancer survivorship care: implications for cost and quality. Cancer. 2012 Jun 01; 118(11):2837-45.
    View in: PubMed
    Score: 0.020
  47. Primary care perspectives on prostate cancer survivorship: implications for improving quality of care. Urol Oncol. 2013 Aug; 31(6):727-32.
    View in: PubMed
    Score: 0.020
  48. Primary care perspectives on prostate cancer screening. Nurse Pract. 2011 Jun; 36(6):39-44.
    View in: PubMed
    Score: 0.020
  49. Understanding early functional recovery after robotic prostatectomy. Surg Innov. 2012 Mar; 19(1):5-10.
    View in: PubMed
    Score: 0.019
  50. The delivery of prostate cancer care in the United States: implications for delivery system reform. J Urol. 2010 Dec; 184(6):2279-84.
    View in: PubMed
    Score: 0.019
  51. Does robotic technology mitigate the challenges of large prostate size? Urology. 2010 Nov; 76(5):1117-21.
    View in: PubMed
    Score: 0.018
  52. The economic burden of prostate cancer survivorship care. J Urol. 2010 Aug; 184(2):532-8.
    View in: PubMed
    Score: 0.018
  53. Regional differences in early stage bladder cancer care and outcomes. Urology. 2010 Aug; 76(2):391-6.
    View in: PubMed
    Score: 0.018
  54. Intravesical bacille Calmette-Guérin therapy for non-muscle-invasive bladder cancer: effects of concurrent statin therapy. J Am Coll Surg. 2009 Aug; 209(2):248-53.
    View in: PubMed
    Score: 0.017
  55. Measurement of benign prostatic hyperplasia treatment effects on male sexual function. Int J Impot Res. 2009 Sep-Oct; 21(5):267-74.
    View in: PubMed
    Score: 0.017
  56. Laparoscopic retroperitoneal lymph node dissection for low-stage testicular cancer. J Endourol. 2008 Jul; 22(7):1485-9.
    View in: PubMed
    Score: 0.016
  57. The distribution of histological subtypes of renal tumors by decade of life using the 2004 WHO classification. J Urol. 2008 Feb; 179(2):439-43; discussion 443-4.
    View in: PubMed
    Score: 0.016
  58. The effect of body mass index on PSA levels and the development, screening and treatment of prostate cancer. Nat Clin Pract Urol. 2007 Nov; 4(11):605-14.
    View in: PubMed
    Score: 0.015
  59. Urinary Retention Evaluation and Catheterization Algorithm for Adult Inpatients. JAMA Netw Open. 2024 Jul 01; 7(7):e2422281.
    View in: PubMed
    Score: 0.012
  60. Attitudes and barriers toward video visits in surgical care: Insights from a nationwide survey among surgeons. Surgery. 2024 Jul; 176(1):115-123.
    View in: PubMed
    Score: 0.012
  61. Hormonal Therapy and Radiation Therapy in Prostate Cancer: 5-Year Outcomes From a Trial Evaluating Combined Androgen Blockade With 5-Alpha Reductase Inhibitors as an Alternative to Gonadotropin Releasing Hormone Agonists. Clin Genitourin Cancer. 2024 Aug; 22(4):102103.
    View in: PubMed
    Score: 0.012
  62. Utilization and Timing of Cystoscopy for Hematuria Evaluation by Advanced Practice Providers and Urologists. Urology. 2024 Jun; 188:80-86.
    View in: PubMed
    Score: 0.012
  63. Patient perspectives on factors influencing active surveillance adherence for low-risk prostate cancer: A qualitative study. Cancer Med. 2024 Jan; 13(1):e6847.
    View in: PubMed
    Score: 0.012
  64. Determinants of Bone-Modifying Agent Prescribing for Metastatic Castration-Resistant Prostate Cancer in a National Health Care Delivery System. JCO Oncol Pract. 2024 01; 20(1):59-68.
    View in: PubMed
    Score: 0.012
  65. Comparing Patient-reported Functional Outcomes After Radical Prostatectomy in Historical and Contemporary Practice. J Urol. 2023 Nov; 210(5):771-777.
    View in: PubMed
    Score: 0.011
  66. Mental health care utilization among men with castration-resistant prostate cancer receiving abiraterone or enzalutamide. Cancer Med. 2023 08; 12(15):16490-16501.
    View in: PubMed
    Score: 0.011
  67. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries. Eur Urol. 2023 05; 83(5):393-401.
    View in: PubMed
    Score: 0.011
  68. Guidelines for Sexual Health Care for Prostate Cancer Patients: Recommendations of an International Panel. J Sex Med. 2022 11; 19(11):1655-1669.
    View in: PubMed
    Score: 0.011
  69. Exploring Variation in the Receipt of Recommended Active Surveillance for Men with Favorable-Risk Prostate Cancer. J Urol. 2022 09; 208(3):600-608.
    View in: PubMed
    Score: 0.010
  70. Implementation of patient-reported outcome measures into health care for men with localized prostate cancer. Nat Rev Urol. 2022 05; 19(5):263-279.
    View in: PubMed
    Score: 0.010
  71. Comparison of the treatment of men with prostate cancer between the US and England: an international population-based study. Prostate Cancer Prostatic Dis. 2023 06; 26(2):287-292.
    View in: PubMed
    Score: 0.010
  72. Urinary incontinence and use of incontinence surgery after radical prostatectomy: a national study using patient-reported outcomes. BJU Int. 2022 07; 130(1):84-91.
    View in: PubMed
    Score: 0.010
  73. TrueNTH Sexual Recovery Intervention for couples coping with prostate cancer: Randomized controlled trial results. Cancer. 2022 Apr 01; 128(7):1513-1522.
    View in: PubMed
    Score: 0.010
  74. Developing a Patient-Centered Model of Prostate Cancer Care: Patient Satisfaction With a Survivorship Program Embedded in Urologic-Oncologic Care. Urology. 2022 02; 160:161-167.
    View in: PubMed
    Score: 0.010
  75. Improving Guideline Adherence in Urology. Eur Urol Focus. 2022 09; 8(5):1545-1552.
    View in: PubMed
    Score: 0.010
  76. Using an Automated Electronic Health Record Score To Estimate Life Expectancy In Men Diagnosed With Prostate Cancer In The Veterans Health Administration. Urology. 2021 09; 155:70-76.
    View in: PubMed
    Score: 0.010
  77. Understanding Active Surveillance for Prostate Cancer. JCO Oncol Pract. 2021 11; 17(11):e1678-e1687.
    View in: PubMed
    Score: 0.010
  78. Urology Workforce Changes and Implications for Prostate Cancer Care Among Medicare Enrollees. Urology. 2021 09; 155:77-82.
    View in: PubMed
    Score: 0.010
  79. Primary Care Providers' Perceptions About Participating in Low-Risk Prostate Cancer Treatment Decisions. J Gen Intern Med. 2021 02; 36(2):447-454.
    View in: PubMed
    Score: 0.009
  80. Demand for Surgical Procedures Following COVID-19: The Need for Operational Strategies That Optimize Resource Utilization and Value. Ann Surg. 2020 10; 272(4):e272-e274.
    View in: PubMed
    Score: 0.009
  81. Reconsidering the Trade-offs of Prostate Cancer Screening. N Engl J Med. 2020 09 24; 383(13):1289-1290.
    View in: PubMed
    Score: 0.009
  82. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer. Cancer. 2020 12 01; 126(23):5050-5059.
    View in: PubMed
    Score: 0.009
  83. The Feasibility and Impact of a Presurgical Exercise Intervention Program (Prehabilitation) for Patients Undergoing Cystectomy for Bladder Cancer. Urology. 2020 11; 145:106-112.
    View in: PubMed
    Score: 0.009
  84. Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration. Urol Oncol. 2020 09; 38(9):734.e1-734.e10.
    View in: PubMed
    Score: 0.009
  85. Assessing Genitourinary Cancer Clinical Trial Accrual Sufficiency Using Archived Trial Data. JCO Clin Cancer Inform. 2020 07; 4:614-622.
    View in: PubMed
    Score: 0.009
  86. A measure of case complexity for streamlining workflow in multidisciplinary tumor boards: Mixed methods development and early validation of the MeDiC tool. Cancer Med. 2020 07; 9(14):5143-5154.
    View in: PubMed
    Score: 0.009
  87. Resurrecting immortal-time bias in the study of readmissions. Health Serv Res. 2020 04; 55(2):273-276.
    View in: PubMed
    Score: 0.009
  88. Comparison of Neoadjuvant and Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2020 06; 18(3):201-209.e2.
    View in: PubMed
    Score: 0.009
  89. Reply by Authors. J Urol. 2020 02; 203(2):421.
    View in: PubMed
    Score: 0.009
  90. Practice-Level Adoption of Conservative Management for Prostate Cancer. J Oncol Pract. 2019 10; 15(10):e863-e869.
    View in: PubMed
    Score: 0.009
  91. Implications of Cystectomy Travel Distance for Hospital Readmission and Survival. Clin Genitourin Cancer. 2019 12; 17(6):e1171-e1180.
    View in: PubMed
    Score: 0.009
  92. Characterising 'bounce-back' readmissions after radical cystectomy. BJU Int. 2019 12; 124(6):955-961.
    View in: PubMed
    Score: 0.009
  93. External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer. J Urol. 2019 09; 202(3):518-524.
    View in: PubMed
    Score: 0.009
  94. Adoption of Abiraterone and Enzalutamide by Urologists. Urology. 2019 09; 131:176-183.
    View in: PubMed
    Score: 0.008
  95. Association Between Hospital Participation in Medicare Shared Savings Program Accountable Care Organizations and Readmission Following Major Surgery. Ann Surg. 2019 05; 269(5):873-878.
    View in: PubMed
    Score: 0.008
  96. Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer. Urol Oncol. 2019 07; 37(7):462-469.
    View in: PubMed
    Score: 0.008
  97. Urologist Practice Structure and Spending for Prostate Cancer Care. Urology. 2019 Aug; 130:65-71.
    View in: PubMed
    Score: 0.008
  98. Role of Post-Acute Care on Hospital Readmission After High-Risk Surgery. J Surg Res. 2019 02; 234:116-122.
    View in: PubMed
    Score: 0.008
  99. Population Analysis of Male Urethral Stricture Management and Urethroplasty Success in the United States. Urology. 2019 01; 123:258-264.
    View in: PubMed
    Score: 0.008
  100. Michigan Appropriate Perioperative (MAP) criteria for urinary catheter use in common general and orthopaedic surgeries: results obtained using the RAND/UCLA Appropriateness Method. BMJ Qual Saf. 2019 01; 28(1):56-66.
    View in: PubMed
    Score: 0.008
  101. Variation in prostate cancer treatment and spending among Medicare shared savings program accountable care organizations. Cancer. 2018 08; 124(16):3364-3371.
    View in: PubMed
    Score: 0.008
  102. Predictors and Cost of Readmission in Total Knee Arthroplasty. J Arthroplasty. 2018 09; 33(9):2759-2763.
    View in: PubMed
    Score: 0.008
  103. Impact of Accountable Care Organizations on Diagnostic Testing for Prostate Cancer. Urology. 2018 06; 116:68-75.
    View in: PubMed
    Score: 0.008
  104. The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration. J Urol. 2018 09; 200(3):541-548.
    View in: PubMed
    Score: 0.008
  105. Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 06 01; 101(2):376-386.
    View in: PubMed
    Score: 0.008
  106. Early effect of Medicare Shared Savings Program accountable care organization participation on prostate cancer care. Cancer. 2018 02 01; 124(3):563-570.
    View in: PubMed
    Score: 0.008
  107. TrueNTH sexual recovery study protocol: a multi-institutional collaborative approach to developing and testing a web-based intervention for couples coping with the side-effects of prostate cancer treatment in a randomized controlled trial. BMC Cancer. 2017 Oct 02; 17(1):664.
    View in: PubMed
    Score: 0.008
  108. The State of Men's Health Services in the Veterans Health Administration. Curr Urol Rep. 2017 Sep 18; 18(11):88.
    View in: PubMed
    Score: 0.008
  109. Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly. Eur Urol. 2018 04; 73(4):491-498.
    View in: PubMed
    Score: 0.008
  110. Functional Outcomes Following Nerve Sparing Prostatectomy Augmented with Seminal Vesicle Sparing Compared to Standard Nerve Sparing Prostatectomy: Results from a Randomized Controlled Trial. J Urol. 2017 09; 198(3):600-607.
    View in: PubMed
    Score: 0.007
  111. Sharp Decline In Prostate Cancer Treatment Among Men In The General Population, But Not Among Diagnosed Men. Health Aff (Millwood). 2017 01 01; 36(1):108-115.
    View in: PubMed
    Score: 0.007
  112. Potential Implications of Shortening Length of Stay Following Radical Cystectomy in a Pre-ERAS Population. Urology. 2017 04; 102:92-99.
    View in: PubMed
    Score: 0.007
  113. Accuracy of Prostate-Specific Antigen Values in Prostate Cancer Registries. J Clin Oncol. 2016 10 10; 34(29):3586-3587.
    View in: PubMed
    Score: 0.007
  114. Implications of evolving delivery system reforms for prostate cancer care. Am J Manag Care. 2016 Sep; 22(9):569-75.
    View in: PubMed
    Score: 0.007
  115. Health Care Integration and Quality among Men with Prostate Cancer. J Urol. 2017 01; 197(1):55-60.
    View in: PubMed
    Score: 0.007
  116. Negative information-seeking experiences of long-term prostate cancer survivors. J Cancer Surviv. 2016 12; 10(6):1089-1095.
    View in: PubMed
    Score: 0.007
  117. Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. Urol Oncol. 2016 09; 34(9):415.e1-6.
    View in: PubMed
    Score: 0.007
  118. Limitations of Prostate-specific Antigen Testing After a Prostate Cancer Diagnosis. Eur Urol. 2016 08; 70(2):209-10.
    View in: PubMed
    Score: 0.007
  119. Prostate Cancer, Version 1.2016. J Natl Compr Canc Netw. 2016 01; 14(1):19-30.
    View in: PubMed
    Score: 0.007
  120. A Model to Optimize Followup Care and Reduce Hospital Readmissions after Radical Cystectomy. J Urol. 2016 May; 195(5):1362-1367.
    View in: PubMed
    Score: 0.007
  121. Expectant management of veterans with early-stage prostate cancer. Cancer. 2016 Feb 15; 122(4):626-33.
    View in: PubMed
    Score: 0.007
  122. Preparing Patients and Partners for Recovery From the Side Effects of Prostate Cancer Surgery: A Group Approach. Urology. 2016 Feb; 88:36-42.
    View in: PubMed
    Score: 0.007
  123. Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol. 2015 Aug; 116(2):179-84.
    View in: PubMed
    Score: 0.007
  124. Veterans Affairs Telemedicine: Bringing Urologic Care to Remote Clinics. Urology. 2015 Aug; 86(2):255-60.
    View in: PubMed
    Score: 0.006
  125. Reply: To PMID 26168998. Urology. 2015 Aug; 86(2):260-1.
    View in: PubMed
    Score: 0.006
  126. Are we targeting the right outcome for sexual health after prostate cancer treatment? Eur Urol. 2015 Oct; 68(4):550-1.
    View in: PubMed
    Score: 0.006
  127. Survivorship and improving quality of life in men with prostate cancer. Eur Urol. 2015 Sep; 68(3):374-83.
    View in: PubMed
    Score: 0.006
  128. Reducing PSA-Based Prostate Cancer Screening in Men Aged?75 Years and Older with the Use of Highly Specific Computerized Clinical Decision Support. J Gen Intern Med. 2015 Aug; 30(8):1133-9.
    View in: PubMed
    Score: 0.006
  129. What couples say about their recovery of sexual intimacy after prostatectomy: toward the development of a conceptual model of couples' sexual recovery after surgery for prostate cancer. J Sex Med. 2015 Feb; 12(2):494-504.
    View in: PubMed
    Score: 0.006
  130. Technology diffusion and prostate cancer quality of care. Urology. 2014 Nov; 84(5):1066-72.
    View in: PubMed
    Score: 0.006
  131. Understanding the relationship between tumor size, gland size, and disease aggressiveness in men with prostate cancer. Urology. 2014 Aug; 84(2):373-8.
    View in: PubMed
    Score: 0.006
  132. Exploring the role of the partner in couples' sexual recovery after surgery for prostate cancer. Support Care Cancer. 2014 Sep; 22(9):2509-15.
    View in: PubMed
    Score: 0.006
  133. Adherence to performance measures and outcomes among men treated for prostate cancer. J Urol. 2014 Sep; 192(3):743-8.
    View in: PubMed
    Score: 0.006
  134. Validating electronic cancer quality measures at Veterans Health Administration. Am J Manag Care. 2014; 20(12):1041-7.
    View in: PubMed
    Score: 0.006
  135. Regional variation in quality of prostate cancer care. J Urol. 2014 Apr; 191(4):957-62.
    View in: PubMed
    Score: 0.006
  136. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA. 2013 Jun 26; 309(24):2587-95.
    View in: PubMed
    Score: 0.006
  137. Technology diffusion and diagnostic testing for prostate cancer. J Urol. 2013 Nov; 190(5):1715-20.
    View in: PubMed
    Score: 0.006
  138. Managed care and the diffusion of intensity-modulated radiotherapy for prostate cancer. Urology. 2012 Dec; 80(6):1236-42.
    View in: PubMed
    Score: 0.005
  139. Certificate of need legislation and the dissemination of robotic surgery for prostate cancer. J Urol. 2013 Jan; 189(1):80-5.
    View in: PubMed
    Score: 0.005
  140. Certificate of need regulations and the diffusion of intensity-modulated radiotherapy. Urology. 2012 Nov; 80(5):1015-20.
    View in: PubMed
    Score: 0.005
  141. Comparative effectiveness of external-beam radiation approaches for prostate cancer. Eur Urol. 2014 Jan; 65(1):162-8.
    View in: PubMed
    Score: 0.005
  142. Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse. Health Aff (Millwood). 2012 Apr; 31(4):750-9.
    View in: PubMed
    Score: 0.005
  143. Identifying better practices for early-stage bladder cancer. Med Care. 2011 Dec; 49(12):1112-7.
    View in: PubMed
    Score: 0.005
  144. Editorial comment. Urology. 2011 Feb; 77(2):279.
    View in: PubMed
    Score: 0.005
  145. Understanding prostate cancer spending growth among Medicare beneficiaries. Urology. 2011 Feb; 77(2):326-31.
    View in: PubMed
    Score: 0.005
  146. Variation in use of lymph node dissection during radical cystectomy for bladder cancer. Urology. 2011 Feb; 77(2):385-90.
    View in: PubMed
    Score: 0.005
  147. Delays in diagnosis and bladder cancer mortality. Cancer. 2010 Nov 15; 116(22):5235-42.
    View in: PubMed
    Score: 0.005
  148. Percent microscopic tumor necrosis and survival after curative surgery for renal cell carcinoma. J Urol. 2010 Mar; 183(3):909-14.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.